2019/03/27 by Caio Júlio César dos Santos Fernandes, Luciana Tamie Kato Morinaga, José Leonidas Alves +4 · 1 citation
Medicine · #Venous Thromboembolism Diagnosis and Management #Atrial Fibrillation Management and Outcomes #Acute Myocardial Infarction Research #Medicine #Cancer #Venous thromboembolism #Incidence (geometry) #Thrombosis #Disease #Intensive care medicine #Cause of death #Population #Venous thrombosis #Internal medicine #Environmental health
paper · pdf · doi:10.1183/16000617.0119-2018
openalex publication_date 2019/03/27 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.